<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01234896</url>
  </required_header>
  <id_info>
    <org_study_id>NICTDP1080</org_study_id>
    <secondary_id>2010-021087-15</secondary_id>
    <nct_id>NCT01234896</nct_id>
  </id_info>
  <brief_title>Single-dose Nicotine Pharmacokinetics With Four Oral Nicotine Replacement Products</brief_title>
  <official_title>Single-dose Nicotine Pharmacokinetics With Four Oral Nicotine Replacement Products. A Study in Healthy Smokers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McNeil AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johnson &amp; Johnson Consumer and Personal Products Worldwide</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single-dose nicotine pharmacokinetics with four oral nicotine replacement products. A study
      in healthy smokers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Forty-four (44) healthy male or female subjects will be included. Single doses of an
      experimental Nicotine medicated chewing gum 6 mg and Nicorette® Freshfruit gum 4 mg and 2 mg
      and NiQuitin™ Mint lozenge 4 mg will be administered in a standardized mode, on four separate
      treatment visits. Periods without nicotine replacement therapy, each lasting for at least 36
      hours, will separate the treatment visits. The subjects will abstain from smoking from 8 pm
      the evening before each treatment visit and until the end of each visit. Blood for
      pharmacokinetic analyses will be drawn before, and at 2, 4, 6, 8, 10, 15, 20, 30, 45, and 60
      minutes as well as at 1.5, 2, 4, 6, 8, 10, and 12 hours after, product administration.
      Subjects will be monitored to capture any adverse events that may occur.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>12 hours post-dose</time_frame>
    <description>Cmax, which is the maximum observed plasma concentration, measured in nanograms/milliliter (ng/mL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve (AUC)(0-t)</measure>
    <time_frame>12 hours post-dose</time_frame>
    <description>AUC(0-t), which is the area under the plasma concentration verses time curve from start of drug administration until the time of the last measurable plasma concentration, calculated as hour * nanograms (ng) per milliliter (mL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC (0-∞)</measure>
    <time_frame>12 hours post-dose</time_frame>
    <description>AUC (0-∞), which is the area under the plasma concentration-vs.-time curve from start of drug administration until infinity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC(10 min)</measure>
    <time_frame>10 minutes post-dose</time_frame>
    <description>AUC(10 min) which is the area under the plasma concentration verses time curve from start of drug administration until 10 minutes</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Tobacco Dependence</condition>
  <arm_group>
    <arm_group_label>Nicotine Gum 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 mg Nicotine medicated gum</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nicotine Gum 4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4 mg Nicotine Gum</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nicotine Gum 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 mg Nicotine Gum</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nicotine Lozenge</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4 mg Nicotine Lozenge</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine Medicated Gum</intervention_name>
    <description>Dosage Form: Gum; Dosage: 6 mg; Frequency: Once; Duration: 30 minutes</description>
    <arm_group_label>Nicotine Gum 6</arm_group_label>
    <other_name>Not marketed</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>4 mg Nicotine Gum</intervention_name>
    <description>Dosage Form: Gum; Dosage: 4 mg; Frequency: Once; Duration: 30 minutes</description>
    <arm_group_label>Nicotine Gum 4</arm_group_label>
    <other_name>Nicorette® Freshfruit gum</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2 mg Nicotine Gum</intervention_name>
    <description>Dosage Form: Gum; Dosage: 2 mg; Frequency: Once; Duration: 30 minutes</description>
    <arm_group_label>Nicotine Gum 2</arm_group_label>
    <other_name>Nicorette® Freshfruit gum</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>4 mg Nicotine Lozenge</intervention_name>
    <description>Dosage Form: Lozenge; Dosage: 4 mg; Frequency: Once; Duration: until dissolved</description>
    <arm_group_label>Nicotine Lozenge</arm_group_label>
    <other_name>NiQuitin™ Mint lozenge</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy subjects, smoking at least 15 cigarettes daily during at least one year
             preceding inclusion and BMI between 17.5 and 30.0 kilograms per square meter and a
             total body weight of at least 55.0 kilograms.

          -  Female participants of child-bearing potential are required to use a medically
             acceptable means of birth control.

          -  A personally signed and dated informed consent document, indicating that the subject
             has been informed of all pertinent aspects of the study.

        Exclusion Criteria:

          -  Pregnancy, lactation or intended pregnancy.

          -  Treatment with an investigational product or donation or loss of blood within 3 month
             preceding the first dose of study medication.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elisabeth Kruse, PhD</last_name>
    <role>Study Director</role>
    <affiliation>McNeil AB</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>McNeil AB Clinical Pharmacology R&amp;D</name>
      <address>
        <city>Lund</city>
        <zip>SE-222 20</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 3, 2010</study_first_submitted>
  <study_first_submitted_qc>November 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2010</study_first_posted>
  <last_update_submitted>July 6, 2012</last_update_submitted>
  <last_update_submitted_qc>July 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Smoking Cessation, Nicotine pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

